Japanese scientists have given so-called "IPS" stem cells to the brain of a patient with Parkinson's disease. The aim of this clinical trial is to verify whether these cells can regenerate dopamine neurons and release symptoms.
Teaminjection of 2.4 million of them capable of giving any type of cell on the left , during the three-hour operation last month. The man at his age of fifty was well tolerated and will now be under surveillance for two years, the Kyoto University said in a statement.
If there is no problem in the next six months, the researchers then implant another 2.4 million cells, this time into the right part of the patient's brain. These iPS cells from healthy donors should growdopamine producer, a neurotransmitter involved in engine management.
In July, Kyoto University announced this clinical trial with seven participants aged 50-69. "I greet patients for their courageous and decisive participation", said Professor Jun Takahashi, quoted the public television channel NHK on Friday.
Pluripotent cells generate new neurons
is marked by degeneration of dopamine neurons and results which are gradually getting worse, such as tremors, limb stiffness and reduced body movements. This affects more than ten million people around the world, according to US. Therapies are currently available "Improving Symptoms without Delaying Progression of Disease"explains the foundation.
This test follows a monkey experimentof human origin that have improved the ability to move who are suffering from Parkinson's disease, according to a study published in the end of August 2017 in a scientific journal nature, Survival of transplanted cells by priming brain injections was observed for two years, with no ,
(iPS for induced pluripotent stem cells), adult cells are brought back to an almost embryonic state by expressing them in four (normally inactive in adult cells). This genetic manipulation gives them the ability to produce any kind (pluripotency), depending on the body where they are transplanted. The use of iPS cells does not represent basic ethical problems, unlike stem cells people.
What to remember
- Researchers from Kyoto University have given 2.4 million pluripotent cells to the brain of the patient.
- These cells from healthy donors will have to regenerate dopamine neurons.
- Overall, a clinical study should include seven patients.
Parkinson's disease: The stem cells in monkeys return disease
Article from Tokyo – AFP released on February 25, 2012
Monkey evolving the equivalentshowed an improvement in their symptoms after injection of human stem cells into their brains. This technique could be tested in humans since 2015.
Monkeys suffering from Parkinson's disease have made significant progress after implanting human stem cells into their brains, Central European scientists said.
Four monkeys whose limbs moved spasmodically (a common symptomfrom And whoever tried to control his body showed signs of improvement three months after surgery, said Jun Takahashi, a professor at , one of the authors of the study published in ,
Six months afterfour test primates were again able to walk in their cage, he added.
June Takahashi said that at the time of implementation, 35%were dopaminergic neurons, and about a tenth of them still lived a year later. In order to improve the effectiveness of the treatment, he would like to increase this survival to 70%. He hopes he will be able to carry out this experiment on humans as early as 2015. " First, we need to increase the number of dopaminergic neurons to reduce the risk " , he explained.
Pluripotent stem cells induced in humans
In a monkey experiment, Jun Takahashi and his team used itbut in the case of medical experience, scientists think they use it (IPSC), created by implanting four types of genes into human skin cells for reprogramming. These induced iPSCs, which are thus generated, return to almost the embryonic phase (undifferentiated).
Use, which is considered very promising by many scientists, is against. Religious groups regard the culture of these cells as unethical, which emphasizes However, there is nothing in Japan to prevent the use of these cells for scientific research.
is one of the main ones after It is also one of the most common causes of motor impairment cerebrovascular disease.